Italy's National Health Institute (ISS) has recommended that pregnant women should get COVID-19 vaccines after the first three months of their pregnancy, Reuters news agency reported on Friday.
The Italian health authority stated that it was advising women to receive two mRNA-based shots in the second and third trimesters of pregnancy.
According to the ISS, its decision was due to growing evidence on the safety of vaccines during pregnancies for both the foetus and the mother.
Women who are breastfeeding can safely get vaccinated, ISS adding, saying that infants can safely absorb antibodies via milk.
Italy is currently administering two vaccines based on messenger RNA (mRNA) technology, one made by BioNTech (Nasdaq:BNTX) in partnership with Pfizer (NYSE:PFE), and a second from Moderna Inc (Nasdaq:MRNA).
Piramal Pharma acquires controlling stake in Yapan Bio
Innorna Nominated for 2026 Prix Galien USA Best Startup Award
Sanofi's MenQuadfi receives EU approval for infants from six weeks
Evaxion to present three-year cancer vaccine data at ESMO Congress 2026
Evaxion presents new preclinical data on cytomegalovirus vaccine EVX-V1
Northwest Biotherapeutics presents on propensity score matching at BNOS 2026
Taiwan biomedical startups hold over 100 business meetings at BIO 2026
SK bioscience to lead Gates Foundation-funded ROTOR project
Anixa Biosciences' breast cancer vaccine technology granted first Korean patent
Transgene expands myvac platform into non-small cell lung cancer with TG4070
Replicate Bioscience awarded Gates Foundation grant to advance srRNA vaccine candidates for TB
Bavarian Nordic secures DKK700m government vaccine contract
Anixa secures Canadian patent milestone for ovarian cancer vaccine
Transgene to present preclinical TG-MVA mpox vaccine data at World Congress on Infectious Diseases